

practice notes

November 2009

NMMC Acute Stroke Unit earns Silver Performance Award

Earl C. Coleman Jr., quality improvement initiatives director with the American Heart Association/American Stroke Association, presented the Silver Performance Award to **North Mississippi Medical Center's Acute Stroke Unit** on Oct. 16. The Silver Award is given to hospitals in which 85 percent of eligible stroke patients are treated according to nationally recognized stroke care guidelines for 12 consecutive months established and promoted by the association through the Get With The Guidelines program.

Local Physicians Pioneer New System to Diagnose & Treat Bile Duct Conditions

Gastroenterologists at NMMC recently introduced a new procedure to diagnose and treat problems in the liver, pancreas and bile ducts.

Using the SpyGlass® Direct Visualization System, physicians can more easily diagnose and treat bile duct stones, suspected malignancies, bile and pancreatic duct obstruction and cystic lesions. A miniature 6,000-pixel fiber optic probe that attaches to a camera provides the doctor a direct view of a patient's biliary or pancreatic ducts.

Dr. Stephen Amann, medical director of the Center for Digestive Health, LLC, and Dr. John Phillips perform the procedure at NMMC, the only hospital in north Mississippi with the technology. This new technique overcomes some of the visual challenges of conventional Endoscopic Retrograde Cholangiopancreatography (ERCP), a procedure used for many years.

Traditionally in an ERCP procedure, an endoscope is inserted through a patient's mouth, through his stomach and into the first part of the small intestine to view the entrance to the biliary and pancreatic system. After injecting water soluble contrast into the common bile

duct, two-dimensional X-rays may be taken but often don't provide enough information for a complete diagnosis. Sometimes the physician passes small catheters to obtain tissue samples; unfortunately, many of these tests are inconclusive, requiring repeat procedures or additional testing.

The SpyGlass catheter is placed through the endoscope and into the area of interest. The catheter can be steered in four directions to thoroughly inspect the area. "The fiberoptic probe is quite small, and it allows us to look directly into the bile duct without having to interpret an X-ray," Dr. Amann said. "In the past, it could be difficult to determine where to obtain tissue samples. With this new system, we have optical guidance."

Like all endoscopic procedures, the SpyGlass procedure is done on an outpatient basis under moderate sedation. For more information, call 1-800-THE DESK (1-800-843-3375) or visit www.tupelogi.com.

Dr. Hill Chairs WMA Meeting

Edward Hill, M.D., attended the World Medical Association (WMA) meeting in New Delhi, India, on Oct. 14-17. Dr. Hill, chair of the 23-member Council, met preceding the opening of the Assembly. This year the Assembly accepted into membership the Malawi Medical Association, bringing the total of national medical association members to 95, representing approximately 9 million physicians worldwide.

NMMC Honors Dr. Rosa as Acute Rehab Physician of the Year

NMMC staff recently honored **Louis Rosa III, M.D.**, as the Acute Rehabilitation Physician of the Year 2009.

The award is given annually by NMMC's Acute Rehabilitation staff to a physician who exemplifies characteristics that foster good patient care and patient success in rehabilitation. The presentation was made during the National Rehabilitation Awareness Celebration in September.



NORTH MISSISSIPPI
MEDICAL CENTER

A monthly newsletter for physicians, certified nurse practitioners
and other health care professionals.

To submit information, call (662) 377-2371.



Dr. Rosa is a neurosurgeon with North Mississippi Neurosurgical Services, P.A. He received his medical training at Georgetown University School of Medicine. Following a surgical internship at the National Naval Medical Center in Bethesda, Md., Dr. Rosa returned to Georgetown University School of Medicine for his neurosurgery residency.

He was a senior investigator and staff neurosurgeon in the Surgical Neurology Branch at the National Institutes of Health. He is board certified by the American Board of Neurological Surgery. Dr. Rosa is a member of the American Medical Association, Mississippi State Medical Association and American Association of Neurological Surgery.

NMMC Rehab Recognized

NMMC's Rehabilitation Institute and Skilled Nursing Facility recently won the Mississippi Recreation and Parks Association award for Therapeutic Agency or Special Event in Recognition of Outstanding Examples of Innovative Programming and Integration. The award was given for a fishing outing that NMMC staff members took with rehabilitation patients to Ballard Park.

Local Neurologist Attains Board Re-Certification

Justin Graff, M.D., has recently been re-certified by the American Board of Psychiatry and Neurology in the specialties of Neurology and Clinical Neurophysiology.

Dr. Graff is a summa cum laude graduate of the University of Iowa in biology. He graduated in the top 5 percent of his medical school class at the University of Iowa College of Medicine. He subsequently did an internship in internal medicine and residency training in Neurology at the University of Iowa Hospitals and Clinics, where he also served as chief resident. He completed fellowship training in Clinical Neurophysiology at Mayo Clinic in Rochester, Minnesota.

Dr. Graff practices adult neurology with Tupelo Neurology Clinic, P.A., and joined the NMMC medical staff in 1998.

IRB Approves, Renews Studies

The NMHS Institutional Review Board (IRB) currently oversees more than 90 biomedical and behavioral studies. The IRB meets monthly and the following studies were approved and renewed at the October meeting.

New Studies

Study: A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNa-2a and ribavirin in HCV genotype 1 infected subjects who failed to respond or relapsed following at least one course of PegIFNa-2a/b and RBV therapy (TMC435-TiDPI6-C206)

Investigators: John Phillips, M.D. (PI); Digestive Health Specialists

Summary: The purpose of this study is to determine how well TMC435 will work on slowing down or stopping the growth of the hepatitis C virus when given with pegylated interferon and ribavirin.

Study: DEFEAT PE - Detect fluid early from intra-thoracic impedance monitoring (40006062/D)

Investigators: James Stone, M.D. (PI); Karl Crossen, M.D.; Keith Kyker, M.D.; Chris Bell, ACNP

Summary: The purpose of this study is to collect information on the safety and effectiveness of the Impedance Monitoring Feature that will provide information on the fluid in the lungs through the implanted device.

Study: CHOICE - Carotid stenting for high surgical risk patients; evaluating outcomes through the collection of clinical evidence (06-717)

Investigators: Vishal Sachdev, M.D. (PI); Barry Bertolet, M.D.; Amit Gupta, M.D.

Summary: The purpose of this study is to collect data about patients' medical experiences and conditions following treatment of carotid stenosis using one of Abbott Vascular's carotid stent systems and embolic protection systems.

Study: HCRI DAPT - A prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions (IDE #G080186)

Investigators: Barry Bertolet, M.D. (PI); Cardiology Associates of North Mississippi

Summary: The purpose of this study is to collect information about how dual anti-platelet therapy following a percutaneous coronary intervention (PCI) keeps subjects free from death, heart attack, stroke, bleeding, blood clots and another PCI.



Study: XIENCE V – Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (Study Phase II), XIENCE V USA Long Term Follow Up Cohort and XIENCE V USA Abbott Vascular DAPT cohort (06-374)

Investigators: Barry Bertolet, M.D. (PI); Cardiology Associates of North Mississippi

Summary: The purpose of this study is to evaluate the continued safety and effectiveness of the XIENCE V Everolimus Eluting Coronary Stent System, as well as assess the safety and effectiveness of 12 versus 30 months of blood thinning medications in subjects who are implanted with XIENCE V EECSS.

Study Renewals

Study: ACCESS – Patent Foramen Ovale Closure with the Amplatzer PFO Occluder in Patients with Recurrent Cryptogenic Stroke due to Presumed Paradoxical Embolism through a Patent Foramen Ovale who have Failed Conventional Drug Therapy

Investigators: Barry Bertolet, M.D. (PI); Cardiology Associates of North Mississippi

Summary: The Amplatzer PFO Occluder is a percutaneous, transcatheter occlusion device intended for the non-surgical closure of patent foramen ovale (PFO). The purpose of this registry is to allow access to the Occluder in subjects with a PFO who have already experienced at least two strokes due to presumed embolism passing through a patent foramen ovale and who have failed conventional drug therapy. Enrollment is open.

Study: A Phase II/III, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis (C0524T17)

Investigators: Roger Huey, M.D. (PI); Digestive Health Specialists

Summary: This study will compare the safety and efficacy of an experimental drug, golimumab, to no treatment (placebo injections). Enrollment is open.

Study: A Phase III, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis (C0524T18)

Investigators: Roger Huey, M.D. (PI); Digestive Health Specialists

Summary: This study is the long-term follow-up to the previous study (C0524T17). Enrollment is open.

Study: A Randomized, Double-blind, Phase III Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-resistant Prostate Cancer (CA 180-227)

Investigators: Christopher Croot, M.D. (PI); Hematology and Oncology Associates

Summary: To determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib in addition to docetaxel and prednisone. Enrollment is open.

Study: A Randomized Trial of Temsirolimus versus Sorafenib as Second-line Therapy in Patients with Advanced Renal Cell Carcinoma who have Failed First-line Sunitinib Therapy (3066K1-404-WW)

Investigators: Christopher Croot, M.D. (PI); Hematology and Oncology Associates

Summary: The purpose of this study is to determine whether Torisel and Nexavar are safe and useful in treating advanced kidney cancer. Enrollment is open.

Study: A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma (VEG108844)

Investigators: Christopher Croot, M.D. (PI); Hematology and Oncology Associates

Summary: To provide a direct comparison of the efficacy, safety and tolerability for pazopanib and sunitinib (Sutent). Enrollment is open.





Continuing Medical Education

The CME Program is based in the NMMC Education Department and works to provide quality educational programming that will meet general as well as specific professional needs. Please call (662) 377-3826 or the Consult Line at 1-800-952-8101 if you have CME comments and/or suggestions. Select CME programs are by invitation only and are also subject to change. **Please RSVP upon receipt of invitation.**

November 2-3

2009 Med-Surg Conference

8 a.m., NMMC North Education Center

November 13

2009 Oncology Conference

8 a.m., NMMC North Education Center

November 13

2009 Neuro/Radiology Case Studies

1 p.m., NMMC North Education Center
Room 7/8

Non Profit
US Postage Paid
North MS
Medical Center
38801

830 South Gloster
Tupelo, MS 38801
NORTH MISSISSIPPI
MEDICAL CENTER 